X0206 3 2020-10-27 0 0001439725 BIODESIX INC BDSX 0001377832 Strobeck Matthew 2970 WILDERNESS PLACE, SUITE 100 BOULDER CO 80301 1 0 0 0 Series C Preferred Stock Common Stock 16847 D Series D Preferred Stock Common Stock 115610 D Series E Preferred Stock Common Stock 126503 D Series F Preferred Stock Common Stock 152212 D Series G Preferred Stock Common Stock 279699 D Series H Preferred Stock Common Stock 140877 D Series H Preferred Stock Common Stock 21974 I By Clajer Capital LLC Stock Options (Right to Buy) 6.83 2029-07-15 Common Stock 35158 D Stock Options (Right to Buy) 6.83 2030-04-14 Common Stock 35158 D Stock Options (Right to buy) 23.74 2013-01-30 2022-01-29 Common Stock 3369 D 3% Convertible Debt due June 2021 2021-06-30 Common Stock 18714 I By Clajer Capital LLC 3% Convertible Debt due June 2021 2021-06-30 Common Stock 76631 D 3% Convertible Debt due June 2021 2021-06-30 Common Stock 3522 I By UGMA Account 3% Convertible Debt due June 2021 2021-06-30 Common Stock 3522 I By UGMA Account 3% Convertible Debt due June 2021 2021-06-30 Common Stock 3522 I By UGMA Account 3% Convertible Debt due June 2021 2021-06-30 Common Stock 3522 I By UGMA Account Every share of Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") is convertible into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") upon the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock has no expiration date. The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. This option vested in 12 successive, equal monthly installments measured from April 1, 2019. This option vests in 12 successive, equal monthly installments measured from April 1, 2020. This Convertible Debt pays interest at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt is unpaid, the outstanding principal and unpaid accrued interest shall be automatically converted into Common Stock at the completion of the IPO. The conversion price will be equal to 80% of the price per share paid for the Common Stock sold in the IPO. The conversion price is $14.40, or 80% of the $18 price per share paid for the Common Stock sold in the IPO. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Exhibit List Exhibit 24 - Power of Attorney /s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck 2020-10-27